LCTX — Lineage Cell Therapeutics Share News
0.000.00%
Last trade - 00:00- $252.91m
- $201.01m
- $14.56m
Brief: Lineage Cell Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
Lineage Cell rises on deal with Roche to develop, sell eye disorder therapy
Brief: Lineage Establishes Exclusive Worldwide Collaboration With Genentech
Media: Roche's Genentech licenses rights to experimental eye cell therapy from Lineage - WSJ
Brief: Opregen® Clinical Data Presented At 125Th Annual American Academy Of Ophthalmology Meeting
Brief: Lineage Posts Quarterly Loss Per Share Of $0.05
Brief: Lineage Highlights Additional Progress From Clinical Cell Therapy Programs
Brief: Lineage Cell Therapeutics Says Intends To Meet With FDA On Clinical Development Plan For Opregen
Lineage Cell Therapeutics: Gains on plans to restart clinical testing of spinal cord therapy
Brief: Lineage Cell Therapeutics Says Opc1 Cell Therapy For The Treatment Of Spinal Cord Injury To Return To Clinical Testing
Brief: Lineage Cell Therapeutics - Announces Exclusive Option Agreement With Amasa Therapeutics For Supply And Use Of Clinical-Grade Hystem
Brief: Lineage Cell Therapeutics Announces Kevin L. Cook To Join As Chief Financial Officer
Brief: Lineage Cell Therapeutics Set To Join Russell 3000® Index And Russell Microcap® Index
Brief: Lineage Cell Reports Additional Retinal Tissue Restoration Cases In Dry AMD Patients Treated With Opregen RPE Cells
Brief: Lineage Reports First Quarter 2021 Financial Results And Highlights Significant Progress With All Three Clinical Programs
Brief: Lineage Cell Therapeutics Says Increased Size Of Board To Nine
Brief: OpRegen Data Continues To Show Improvements In Patients - Lineage Cell Therapeutics
Brief: Lineage Cell Therapeutics Inc - On April 20, 2021, Board Increased Size Of Board To Eight And Appointed Dipti Amin As Member Of Board
Brief: Lineage Announces Worldwide License Agreement With Immunomic Therapeutics For An Allogeneic Cell-Based Cancer Immunotherapy Based On Its Vac Platform